Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$1.12 -4.7%	$1.24	$0.64 ▼ $2.92	$48.04M	-0.73	31,701 shs	7,765 shs
FLGC Flora Growth	$20.77 +0.3%	$23.01	$15.15 ▼ $82.29	$11.98M	1.97	19,039 shs	7,319 shs
JSPR Jasper Therapeutics	$2.80 -1.4%	$3.63	$2.27 ▼ $26.05	$46.16M	2.7	224,794 shs	94,742 shs
LTRN Lantern Pharma	$4.08 +0.5%	$4.04	$2.55 ▼ $6.12	$43.85M	1.6	135,788 shs	71,423 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	-3.93%	-5.55%	-21.94%	+6.04%	-11.84%
FLGC Flora Growth	-4.90%	-2.30%	-15.47%	-18.07%	-49.76%
JSPR Jasper Therapeutics	-1.41%	-4.44%	-5.41%	-49.55%	-85.96%
LTRN Lantern Pharma	+0.49%	-9.53%	+1.75%	+35.55%	-1.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	3.1408 of 5 stars	3.5	3.0	3.8	0.8	1.3
FLGC Flora Growth	3.2672 of 5 stars	3.5	5.0	3.6	0.8	0.6
JSPR Jasper Therapeutics	2.9912 of 5 stars	4.3	4.0	1.5	1.7	0.0
LTRN Lantern Pharma	2.5094 of 5 stars	3.5	3.0	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$3.00	166.90% Upside
FLGC Flora Growth	3.00	Buy	$93.00	347.76% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$28.75	926.79% Upside
LTRN Lantern Pharma	3.00	Buy	$25.00	512.75% Upside

Current Analyst Ratings Breakdown

Latest FLGC, LTRN, BRNS, and JSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$29.00 ➝ $25.00
8/5/2025	FLGC Flora Growth	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$30.00
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	3.06	N/A	N/A	$2.52 per share	0.45
FLGC Flora Growth	$52.37M	0.23	N/A	N/A	$6.95 per share	2.99
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$1.45 per share	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$1.16 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.73	N/A	N/A	N/A	N/A	-54.70%	-44.75%	11/5/2025 (Estimated)
FLGC Flora Growth	-$15.91M	-$34.38	N/A	N/A	N/A	-24.86%	-261.57%	-48.06%	11/12/2025 (Estimated)
JSPR Jasper Therapeutics	-$71.27M	-$6.01	N/A	N/A	N/A	N/A	-172.28%	-128.34%	11/6/2025 (Estimated)
LTRN Lantern Pharma	-$20.78M	-$1.78	N/A	N/A	N/A	N/A	-99.89%	-81.58%	11/6/2025 (Estimated)

Latest FLGC, LTRN, BRNS, and JSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.20	-$1.74	-$0.54	-$1.74	N/A	N/A
8/13/2025	Q2 2025	LTRN Lantern Pharma	-$0.53	-$0.40	+$0.13	-$0.40	N/A	N/A
8/7/2025	Q2 2025	BRNS Barinthus Biotherapeutics	-$0.29	-$0.52	-$0.23	-$0.52	N/A	N/A
8/1/2025	Q2 2025	FLGC Flora Growth	-$0.06	-$0.11	-$0.05	-$0.11	$11.77 million	$14.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
FLGC Flora Growth	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	7.89	7.89
FLGC Flora Growth	0.50	0.96	0.61
JSPR Jasper Therapeutics	N/A	2.10	2.10
LTRN Lantern Pharma	N/A	3.52	3.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
FLGC Flora Growth	36.01%
JSPR Jasper Therapeutics	79.85%
LTRN Lantern Pharma	28.62%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	10.70%
FLGC Flora Growth	12.56%
JSPR Jasper Therapeutics	4.60%
LTRN Lantern Pharma	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.72 million	36.36 million	N/A
FLGC Flora Growth	280	579,000	506,000	Not Optionable
JSPR Jasper Therapeutics	20	16.25 million	15.51 million	Optionable
LTRN Lantern Pharma	20	10.80 million	9.88 million	Optionable

FLGC, LTRN, BRNS, and JSPR Headlines

Recent News About These Companies

Lantern Pharma Reports Q2 2025 Earnings and Strategic Progress

August 22, 2025 | msn.com

RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26

August 19, 2025 | miamiherald.comM

RedChip Companies, Inc.: RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26

August 19, 2025 | finanznachrichten.de

Lantern Pharma Narrows Loss in Q2

August 14, 2025 | aol.comA

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

August 13, 2025 | businesswire.com

Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy

August 7, 2025 | theglobeandmail.com

Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Grows By 109.5%

August 6, 2025 | marketbeat.com

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

August 4, 2025 | businesswire.com

Lantern Pharma (LTRN) Gets a Buy from Lake Street

August 4, 2025 | theglobeandmail.com

Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan

July 31, 2025 | theglobeandmail.com

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

July 31, 2025 | businesswire.com

Lantern Pharma Appoints Dr. Schalop to Board

July 30, 2025 | msn.com

Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology

July 28, 2025 | theglobeandmail.com

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

July 28, 2025 | businesswire.com

Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

July 26, 2025 | miamiherald.comM

Lantern reports complete response in pretreated Lymphoma patient with LP-284

July 24, 2025 | msn.com

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

July 23, 2025 | businesswire.com

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

July 21, 2025 | businesswire.com

IBN Initiates Coverage of Lantern Pharma Inc.

July 16, 2025 | finance.yahoo.com

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

July 15, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC, LTRN, BRNS, and JSPR Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$1.12 -0.06 (-4.72%)

Closing price 08/29/2025 03:58 PM Eastern

Extended Trading

$1.12 0.00 (-0.36%)

As of 08/29/2025 07:30 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Flora Growth NASDAQ:FLGC

$20.77 +0.07 (+0.34%)

Closing price 08/29/2025 03:57 PM Eastern

Extended Trading

$19.80 -0.97 (-4.67%)

As of 08/29/2025 04:13 PM Eastern

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

Jasper Therapeutics NASDAQ:JSPR

$2.80 -0.04 (-1.41%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.84 +0.05 (+1.61%)

As of 08/29/2025 07:51 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Lantern Pharma NASDAQ:LTRN

$4.08 +0.02 (+0.49%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$4.06 -0.02 (-0.49%)

As of 08/29/2025 07:57 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time